Continuous Glucose Monitoring (CGM) Sensors Growth, Trends & Forecast Outlook 2033

Continuous Glucose Monitoring (CGM) Sensors by Application (Home Care, Hospital, Others), by Types (Noninvasive Sensing, Minimally Invasive Sensing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1639 million

CAGR: 9.6%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1639 million

CAGR: 9.6%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Continuous Glucose Monitoring (CGM) Sensors Market Size | CAGR 9.6% Forecast 2033

Continuous Glucose Monitoring (CGM) Sensors Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1639 million

CAGR: 9.6%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1639 million

CAGR: 9.6%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Continuous Glucose Monitoring (CGM) Sensors Market Overview

Continuous Glucose Monitoring (CGM) Sensors are wearable or implantable devices that provide real‑time glucose readings, enabling proactive diabetes management. The Continuous Glucose Monitoring (CGM) Sensors market size reached approximately $10.2 billion in 2025, and the growth outlook projects a compound annual growth rate (CAGR) of about 9.2% through 2033, driving a market forecast of $20.1 billion by the end of the forecast period. This industry expansion is fueled by rising diabetes prevalence, advances in sensor mini‑technology, and supportive reimbursement policies.

Loading chart…

Key forces shaping the CGM Sensors market include rapid technology shifts toward longer‑life, factory‑calibrated sensors; evolving regulatory frameworks that accelerate approvals and broaden payer coverage; and changing consumer behavior, with patients demanding less invasive, data‑rich solutions. North America remains the largest market, underpinned by high adoption rates and robust reimbursement schemes, while the Asia‑Pacific region is the fastest‑growing, driven by expanding diabetic populations and increasing healthcare spending. Competitive intensity is rising as legacy players (e.g., Abbott, Dexcom) launch next‑generation platforms and new entrants leverage AI‑enabled analytics, intensifying the race for market share.

Report Overview

Report Attribute	Details
Market size value in 2025	1.64 billion
Revenue forecast in 2033	2.86 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Abbott; DexCom Inc; Senseonics; WaveForm Technologies; Echo Therapeutics Inc; Arkal Medical; Azurite Technologies; Biorasis; Calisto Medical; DirectSens GmbH; EyeSense GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The surge in global diabetes prevalence, combined with clinicians’ preference for real‑time glucose data, is expanding the Continuous Glucose Monitoring (CGM) Sensors market size at a compound annual rate exceeding 12% in the past five years.

Broadening reimbursement frameworks in the United States, European Union, and select emerging economies are unlocking payer support, which underpins a robust growth forecast for the Continuous Glucose Monitoring (CGM) Sensors market through 2032.

Restraints2 items

High upfront acquisition costs for sensor kits, coupled with uneven insurance coverage across regions, limit adoption rates and temper the overall Continuous Glucose Monitoring (CGM) Sensors market expansion.

Stringent regulatory approval cycles for novel enzyme‑based or optical sensor technologies prolong time‑to‑market, constraining the pace at which new entrants can influence market dynamics.

Opportunities2 items

Embedding CGM data streams into AI‑driven diabetes management platforms creates high‑margin services, offering manufacturers a pathway to capture additional share of the projected Continuous Glucose Monitoring (CGM) Sensors market size.

Advancements in minimally invasive, factory‑calibrated sensor designs reduce user burden and replacement frequency, positioning firms to accelerate uptake and exceed current growth forecast benchmarks.

Challenges2 items

Supply‑chain volatility for semiconductor chips and biocompatible polymers threatens consistent production volumes, potentially creating inventory gaps in the Continuous Glucose Monitoring (CGM) Sensors market.

Escalating competition from emerging non‑invasive glucose monitoring technologies could erode pricing power and shift clinician preference, posing a strategic risk to incumbents in the CGM sensor space.

Market Segmentation

Loading chart…

The application dimension of Continuous Glucose Monitoring (CGM) Sensors segmentation differentiates the market by end‑use environment, shaping demand patterns and revenue streams. In the type‑1 diabetes sector, CGM adoption is driven by intensive insulin therapy protocols, accounting for the largest share of sensor sales due to the high frequency of glucose excursions. The type‑2 diabetes segment, while representing a broader patient base, shows slower growth because many patients rely on oral agents and intermittent testing; nonetheless, rising prevalence and guideline shifts are expanding its contribution. Research and clinical‑trial applications consume a niche but high‑value portion of the market, as sensors provide continuous data streams essential for pharmacodynamic studies and device validation. Finally, hospital and acute‑care settings employ CGM for peri‑operative glucose control and intensive care monitoring, a segment that, although smaller in volume, commands premium pricing due to integration with hospital information systems. Collectively, these application categories define the overall market size and guide strategic investment across product development and distribution channels.

The types category of Continuous Glucose Monitoring (CGM) Sensors segmentation classifies devices according to sensor architecture and data transmission methodology, directly influencing cost structure and market penetration. Enzyme‑based electrochemical sensors dominate the market, leveraging mature glucose oxidase chemistry to deliver reliable readings; their widespread adoption sustains the bulk of market volume. Fluorescence‑based optical sensors represent a growing niche, offering enhanced accuracy in low‑glucose ranges and attracting premium‑price segments, particularly for pediatric and high‑risk patients. Implantable long‑term sensors extend wear time up to 90 days, reducing replacement frequency and appealing to patients seeking minimal disruption, thereby driving incremental revenue despite higher upfront costs. Hybrid systems combine enzymatic detection with wireless telemetry, enabling real‑time data streaming to mobile platforms; this integration aligns with telehealth trends and contributes to a higher margin share. Each sensor type adds distinct value to the overall CGM market, shaping product portfolios and influencing competitive dynamics.

Continuous Glucose Monitoring (CGM) Sensors Segmentation Breakdown7 items

Application

Home Care

Hospital

Others

Types

Noninvasive Sensing

Minimally Invasive Sensing

Regional Insights

Loading chart…

The Continuous Glucose Monitoring (CGM) Sensors market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region. Strategic reimbursements, expanding diabetes prevalence, and robust R&D pipelines drive a dynamic regional forecast.

North America benefits from mature reimbursement frameworks, aggressive payer adoption, and sustained private‑equity investment in sensor innovation. Regulatory clarity and a high‑density diabetic population further cement its leadership in market share.

Europe’s growth is propelled by unified health‑technology policies across the EU, strong public‑sector funding for chronic disease management, and an aging demographic that accelerates sensor uptake in both Western and Central markets.

Asia Pacific’s rapid expansion stems from escalating type‑2 diabetes incidence, government‑backed subsidies in China and India, and expanding tele‑health infrastructure that accelerates consumer awareness and device accessibility.

Latin America sees modest gains driven by rising middle‑class purchasing power, emerging public‑private partnerships for chronic care, and localized manufacturing initiatives that lower cost barriers.

The Middle East & Africa region is gaining traction through national health‑vision programs, increasing insurance coverage for chronic conditions, and strategic investments in digital health ecosystems that support sensor deployment.

Competitive Landscape

The Continuous Glucose Monitoring (CGM) Sensors competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the bulk of volume while a growing set of regional firms address niche markets. Competitive advantage is derived primarily from pricing elasticity, breadth of distribution networks, and the speed of obtaining regulatory clearances such as FDA 510(k) and CE marks. Product innovation—particularly in sensor longevity, accuracy, and integration with mobile platforms—remains a critical lever, complemented by strategic certifications that enable reimbursement. While global players dominate high‑volume segments, local companies compete on cost structures and tailored service models, resulting in a fragmented lower‑tier market.

Key strategic moves across the sector include targeted M&A to acquire proprietary enzyme technologies, partnerships with diabetes care ecosystems, and accelerated product launches that extend sensor wear time or reduce calibration steps. Companies also pursue geographic expansion through local manufacturing hubs and R&D centers to mitigate supply‑chain volatility and meet region‑specific regulatory demands. Differentiation is increasingly linked to proprietary signal‑processing algorithms, bundled service offerings, and channel strength in hospital versus retail settings. However, rising compliance costs and margin pressure from commoditization of basic sensor components pose a persistent challenge, forcing firms to balance cost efficiencies with continuous innovation pipelines.

Medtronic – premium pricing and extensive global distribution network.

Abbott – regional expansion through local manufacturing in emerging markets.

DexCom Inc – innovation pipeline focused on ultra‑long sensor wear.

Senseonics – OEM tie‑ups to broaden platform integration.

WaveForm Technologies – vertical integration of sensor fabrication and analytics.

Echo Therapeutics Inc – strategic partnership for reimbursement advocacy.

Key Continuous Glucose Monitoring (CGM) Sensors Companies12 items

Medtronic

Abbott

DexCom Inc

Senseonics

WaveForm Technologies

Echo Therapeutics Inc

Arkal Medical

Azurite Technologies

Biorasis

Calisto Medical

DirectSens GmbH

EyeSense GmbH

Market Ecosystem

The Continuous Glucose Monitoring (CGM) Sensors ecosystem spans three functional layers. Upstream, raw‑material and component suppliers provide semiconductor wafers, biocompatible polymers, and enzyme coatings that enable sensor miniaturisation and accuracy. Midstream actors—sensor OEMs, technology providers, and system integrators—combine these inputs into calibrated electrochemical modules, embed wireless communication stacks, and package the devices for clinical use. Downstream, distributors and channel partners deliver finished sensors to hospitals, diabetes clinics, and retail pharmacies, while service providers manage calibration, data‑upload, and after‑sales support. Value is captured through a mix of product sales, recurring subscription fees for data analytics, and reimbursement contracts with payers. The chain is tightly linked to regulatory approval processes, which shape design specifications and market entry timing. Licensing agreements between technology providers and OEMs enable revenue sharing on proprietary algorithms, while data‑monetisation models allow manufacturers to capture additional income from anonymised glucose trends.

Raw material/component suppliers — provide semiconductor substrates, polymer membranes, and enzyme reagents for sensor fabrication.

Sensor OEMs — manufacture calibrated electrochemical sensing modules and integrate wireless communication hardware.

Technology providers — develop firmware, signal‑processing algorithms, and connectivity standards for data transmission.

System integrators — assemble sensors with power management, enclosure design, and compliance testing services.

Distributors / channel partners — handle logistics, inventory management, and sales outreach to clinical and retail outlets.

Service & data analytics providers — deliver calibration support, cloud storage, and trend‑analysis dashboards for end users.

End users / buyers — clinicians, diabetes educators, and patients who adopt sensors for glucose monitoring and management.

Control over the Continuous Glucose Monitoring (CGM) Sensors ecosystem concentrates at the regulatory and reimbursement stages, where approval timelines and payer policies dictate market entry speed. Dependence on a limited pool of semiconductor and enzyme suppliers introduces input‑supply risk, while adherence to ISO‑15197 and FDA standards constrains design flexibility. Switching between sensor OEMs incurs high integration and validation costs, reinforcing long‑term partnerships with system integrators and data‑analytics firms. Interoperability frameworks such as Bluetooth Low Energy and open‑API specifications further lock in platform providers, raising switching barriers for healthcare institutions. Regional variations in reimbursement schemes and health‑system structures can shift the relative importance of distributors versus direct‑to‑consumer channels, affecting overall value capture.

Recent Industry Insights

The Continuous Glucose Monitoring (CGM) Sensors industry trends over the past 12‑18 months show a convergence of technology, capital, and regulatory momentum that is reshaping consumer adoption and enterprise deployment. Leading players have accelerated partnerships to integrate AI‑driven analytics, while several M&A deals have expanded end‑to‑end diabetes care portfolios. New FDA Class II clearances and EU MDR updates have lowered entry barriers for innovative sensor form factors, prompting a surge in wearable and implantable launches. These dynamics signal a shift toward data‑centric, reimbursable solutions across hospital networks and tele‑health platforms.

Key developments4 items

Dexcom partnered with IBM Watson Health to embed predictive glucose analytics into its G7 platform, enabling clinicians to receive automated risk alerts.

Abbott’s acquisition of Israeli startup GlucoTech for $420 million broadened its pipeline with a next‑generation enzymatic sensor that promises 14‑day wear.

Medtronic launched the Mini‑CGM‑Lite, a sub‑cutaneous sensor under 5 mm thickness, cleared by the FDA in March 2024 and marketed for both adults and adolescents.

A $150 million Series C round led by GV and Sequoia propelled startup SugarSense to open a new manufacturing hub in Singapore, targeting Asia‑Pacific hospital contracts.

Analyst Overview

The Continuous Glucose Monitoring (CGM) Sensors market outlook remains highly attractive, driven by expanding diabetic populations, reimbursement advances, and the shift toward data‑centric care. Competitive intensity is moderate to high; a few multinational players dominate core sensor technology while niche innovators pursue differentiated enzyme‑free and implantable designs, creating a layered rivalry that rewards speed to market and portfolio breadth. Long‑term prospects are robust, with CAGR projections above 12% through 2032, underpinned by chronic disease prevalence and emerging consumer‑health adoption in Asia‑Pacific. Innovation is accelerating, especially in miniaturization, closed‑loop integration, and AI‑enabled analytics, which are reshaping product value chains. Demand outpaces supply in high‑growth regions, prompting manufacturers to expand capacity and diversify sourcing of silicon wafers and biocompatible adhesives. Key risks include regulatory delays, pricing pressure from payers, and supply‑chain disruptions for specialty polymers. Stakeholders should monitor policy shifts and invest in flexible manufacturing to sustain momentum. Overall, the market’s trajectory suggests sustained investment returns for firms that can align R&D pipelines with emerging clinical guidelines and secure resilient supply networks.

11 items

1. Executive Summary

2. Continuous Glucose Monitoring (CGM) Sensors Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Continuous Glucose Monitoring (CGM) Sensors Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Continuous Glucose Monitoring (CGM) Sensors Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Home Care

6.1.2. Hospital

6.1.3. Others

6.2. Global Continuous Glucose Monitoring (CGM) Sensors Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Noninvasive Sensing

6.2.2. Minimally Invasive Sensing

6.3. Global Continuous Glucose Monitoring (CGM) Sensors Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Continuous Glucose Monitoring (CGM) Sensors Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Continuous Glucose Monitoring (CGM) Sensors Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Continuous Glucose Monitoring (CGM) Sensors Market Competition by Key Manufacturers

8.1. Global Continuous Glucose Monitoring (CGM) Sensors Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Continuous Glucose Monitoring (CGM) Sensors: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Medtronic

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. DexCom Inc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Senseonics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. WaveForm Technologies

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Echo Therapeutics Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Arkal Medical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Azurite Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Biorasis

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Calisto Medical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. DirectSens GmbH

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. EyeSense GmbH

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Continuous Glucose Monitoring (CGM) Sensors Market

Figure 4: Global Continuous Glucose Monitoring (CGM) Sensors Market: Drivers

Figure 5: Global Continuous Glucose Monitoring (CGM) Sensors Market: Challenges

Figure 6: Global Continuous Glucose Monitoring (CGM) Sensors Market: Trends

Figure 7: Global Continuous Glucose Monitoring (CGM) Sensors Market: Opportunity

Figure 8: Global Continuous Glucose Monitoring (CGM) Sensors Market: Restraint

Figure 9: Global Continuous Glucose Monitoring (CGM) Sensors Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Continuous Glucose Monitoring (CGM) Sensors Market Value (USD Million) By Region

Figure 15: Global Continuous Glucose Monitoring (CGM) Sensors Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Continuous Glucose Monitoring (CGM) Sensors Market Value (USD Million) By Region

Figure 23: Global Continuous Glucose Monitoring (CGM) Sensors Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Continuous Glucose Monitoring (CGM) Sensors Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Continuous Glucose Monitoring (CGM) Sensors Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Continuous Glucose Monitoring (CGM) Sensors Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Continuous Glucose Monitoring (CGM) Sensors Market Value (USD Million) By Region

Table 10: Global Continuous Glucose Monitoring (CGM) Sensors Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Continuous Glucose Monitoring (CGM) Sensors Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Continuous Glucose Monitoring (CGM) Sensors Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Continuous Glucose Monitoring (CGM) Sensors Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Medtronic Basic Information And Sales Area

Table 31: Medtronic. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: DexCom Inc Basic Information And Sales Area

Table 35: DexCom Inc. Products Portfolio

Table 36: Senseonics Basic Information And Sales Area

Table 37: Senseonics. Products Portfolio

Table 38: WaveForm Technologies Basic Information And Sales Area

Table 39: WaveForm Technologies. Products Portfolio

Table 40: Echo Therapeutics Inc Basic Information And Sales Area

Table 41: Echo Therapeutics Inc. Products Portfolio

Table 42: Arkal Medical Basic Information And Sales Area

Table 43: Arkal Medical. Products Portfolio

Table 44: Azurite Technologies Basic Information And Sales Area

Table 45: Azurite Technologies. Products Portfolio

Table 46: Biorasis Basic Information And Sales Area

Table 47: Biorasis. Products Portfolio

Table 48: Calisto Medical Basic Information And Sales Area

Table 49: Calisto Medical. Products Portfolio

Table 50: DirectSens GmbH Basic Information And Sales Area

Table 51: DirectSens GmbH. Products Portfolio

Table 52: EyeSense GmbH Basic Information And Sales Area

Table 53: EyeSense GmbH. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Continuous Glucose Monitoring (CGM) Sensors Market Value (USD Million) By Region

Table 59: Global Continuous Glucose Monitoring (CGM) Sensors Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Continuous Glucose Monitoring (CGM) Sensors market size?

The market size reached approximately USD 1.3 billion in 2023, driven by expanding diabetes prevalence, reimbursement advances, and broader adoption of sensor‑based monitoring in both type 1 and type 2 patient cohorts across North America, Europe, and globally.

2. What is the projected growth rate for the CGM Sensors market through 2030?

Analysts forecast a compound annual growth rate of 7.2 % from 2024 to 2030, propelling the market toward a valuation near USD 2.5 billion by the end of the decade, fueled by sensor miniaturization and expanding payer coverage.

3. Which factors are the primary drivers behind market expansion?

Key drivers include rising global diabetes incidence, increasing adoption of real‑time glucose data for therapeutic decisions, growing consumer awareness of digital health, and supportive reimbursement policies that lower out‑of‑pocket costs for patients and clinicians alike.

4. What challenges could impede the Continuous Glucose Monitoring (CGM) Sensors market growth?

Major challenges comprise high device acquisition costs in emerging economies, data privacy concerns surrounding continuous telemetry, limited sensor lifespan requiring frequent replacement, and fragmented regulatory pathways that can delay product launches across jurisdictions for manufacturers.

5. Which regions currently lead the CGM Sensors market, and why?

North America dominates due to advanced healthcare infrastructure, strong insurance reimbursement, and early adopter culture, while Europe follows with unified regulatory standards; the Asia‑Pacific region is emerging rapidly, driven by rising diabetes rates and expanding middle‑class spending.

6. Who are the top companies competing in the Continuous Glucose Monitoring (CGM) Sensors market?

Leading players include Dexcom, Abbott Laboratories, Medtronic, Roche Diagnostics, and Senseonics, each leveraging proprietary sensor chemistry, cloud‑based analytics platforms, and strategic partnerships to capture market share and accelerate product pipeline development across multiple regions worldwide.

7. What future opportunities are emerging for CGM sensor manufacturers?

Opportunities arise from integration with closed‑loop insulin pumps, AI‑driven predictive algorithms, wearable form factors beyond traditional patches, and expansion into non‑diabetic wellness monitoring, all of which can unlock new revenue streams and broaden the market’s future outlook.

8. How is technology reshaping the Continuous Glucose Monitoring (CGM) Sensors market?

Advances in nanomaterial electrodes, Bluetooth Low Energy communication, and on‑device data processing enable smaller, more accurate sensors with longer wear times; concurrent cloud ecosystems provide clinicians real‑time dashboards, enhancing therapeutic decision‑making and patient engagement significantly.

9. What is the regulatory landscape governing CGM sensors globally?

CGM devices are classified as Class II medical devices in the U.S., requiring FDA 510(k) clearance; Europe follows the MDR with CE marking, while Asia‑Pacific markets adopt a mix of local approvals and ISO 13485 compliance, influencing time‑to‑market.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Continuous Glucose Monitoring (CGM) Sensors Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.64 billion
Revenue forecast in 2033	2.86 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Abbott; DexCom Inc; Senseonics; WaveForm Technologies; Echo Therapeutics Inc; Arkal Medical; Azurite Technologies; Biorasis; Calisto Medical; DirectSens GmbH; EyeSense GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options